In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.
TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...
In a recent study posted to the bioRxiv* preprint server, researchers elucidated the mechanism of ribonucleic acid (RNA) capping in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Study: ...
A new synthesis method offers hope for creation of advance mRNA vaccines to fight viruses and even cancers. Researchers at Nagoya University in Japan have developed a new chemical-only process that ...
New England Biolabs (NEB ®) announces the release of the Faustovirus Capping Enzyme (FCE), an mRNA capping solution that combines high activity and a broad temperature range to support mRNA ...
As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols™ ExTend Cap AU, ...
The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results